Antigen-specific therapy of rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 8, Issue 2, 2008, Pages 191-199

  Ichim, Thomas E ^a,b   Zheng, Xiufen ^a   Suzuki, Motohiko ^a   Kubo, Norihiko ^a   Zhang, Xusheng ^a   Min, Lisa R ^a   Beduhn, Marianne E ^a   Riordan, Neil H ^b   Inman, Robert D ^c   Min, Wei Ping ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MediStem Laboratories Inc   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Autoimmunity; Dendritic cells; Gene silencing; Immune modulation; Immunotherapy; Rheumatoid arthritis; siRNA

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIGEN; AZATHIOPRINE; COLLAGEN TYPE 2; CORTICOSTEROID; CYCLOSPORIN; DCVAX BRAIN; DENDRITIC CELL VACCINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; ETANERCEPT; FLT3 LIGAND; GOLD SALT; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYELIN BASIC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; POLYGLACTIN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIGENICITY; AUTOIMMUNITY; CLINICAL TRIAL; CLONAL ANERGY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEASIBILITY STUDY; GENE SILENCING; GENE THERAPY; GENOMICS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; RNA TRANSLATION; SYSTEMATIC REVIEW; TUBERCULOSIS; VACCINATION; ANIMAL; ARTHRITIS; IMMUNOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; IMMUNOTHERAPY;

EID: 38949194004     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.2.191     Document Type: Review

References (93)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24
2. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006;63(24):2451-65
3. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932-9
4. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46(2):327-34
5. Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007;12(1):16-21
6. Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum 2006;55(1):163-6
7. Benucci M, Li Gobbi F, Fossi F, et al. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol 2005;11(1):47-9
8. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33(12):2398-408
9. Mackay IR, Rowley MJ. Autoimmune epitopes: autoepitopes. Autoimmun Rev 2004;3(7-8):487-92
10. Kotzin BL, Falta MT, Crawford F, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97(1):291-6
11. Yamada R, Suzuki A, Chang X, et al. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005;10:54-64
12. Massa M, Passalia M, Manzoni SM, et al. Differential recognition of heat-shock protein DNAJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum 2007;56(5):1648-57
13. Kamphuis S, Albani S, Prakken BJ. Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis. Expert Opin Biol Ther 2006;6(6):579-89
14. Fehr K. Autoimmune reactions and rheumatoid arthritis. Eur J Rheumatol Inflamm 1982;5(4):439-56
15. Golds EE, Stephen IB, Esdaile JM, et al. Lymphocyte transformation to connective tissue antigens in adult and juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, and a nonarthritic control population. Cell Immunol 1983;82(1):196-209
16. Fugger L, Rothbard JB, Sonderstrup-McDevitt G. Specificity of an HLA-DRB1 *0401-restricted T cell response to type II collagen. Eur J Immunol 1996;26(4):928-33
17. Cook AD, Rowley MJ, Mackay IR, et al. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 1996;39(10):1720-7
18. Kim WU, Yoo WH, Park W, et al. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000;27(3):575-81
19. Kim WU, Cho ML, Jung YO, et al. Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 2004;327(4):202-11
20. Smolen JS, Steiner G. Are autoantibodies active players or epiphenomena? Curr Opin Rheumatol 1998;10(3):201-6
21. Lundberg K, Nijenhuis S, Vossenaar ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7(3):R458-67
22. von Delwig A, Altmann DM, Isaacs JD, et al. The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum 2006;54(2):482-91
23. Trentham DE, Townes AS, Kang AH. Autoimmnunity to type II collagen an experimental model of arthritis. J Exp Med 1977;146(3):857-68
24. Wooley PH. Immunotherapy in collagen-induced arthritis: past, present, and future. Am J Med Sci 2004;327(4):217-26
25. Williams RO. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol 2007;361:265-84
26. Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43(12):2648-59
27. Allen JB, Wong HL, Costa GL, et al. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993;151(8):4344-51
28. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006;13(2-4):143-57
29. Fukaura H, Kent SC, Pietrusewicz MJ, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98(1):70-7
30. Inobe J, Slavin AJ, Komagata Y, et al. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 1998;28(9):2780-90
31. Baggi F, Andreetta F, Caspani E, et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest 1999;104(9):1287-95
32. Im SH, Barchan D, Fuchs S, et al. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 1999;104(12):1723-30
33. Hultkrantz S, Ostman S, Telemo E. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration. Immunology 2005;116(3):362-72
34. + regulatory T cell clones induced in Peyer's patches. Int Immunol 2003;15(4):525-34
35. Battaglia M, Gianfrani C, Gregori S, et al. IL-10-producing T regulatory type 1 cells and oral tolerance. Ann NY Acad Sci 2004;1029:142-53
36. Sun J, Alison Stalls M, Thompson KL, et al. Cell cycle block in anergic T cells during tolerance induction. Cell Immunol 2003;225(1):33-41
37. Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83(19):7443-6
38. Zhang ZY, Lee CS, Lider O, et al. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990;145(8):2489-93
39. Thompson HS, Harper N, Bevan DJ, et al. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993;16(3):189-99
40. Yoshino S. Antigen-induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after immunization. Cell Immunol 1995;163(1):55-8
41. Kim WU, Lee WK, Ryoo JW, et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 2002;46(4):1109-20
42. Margalit M, Israeli E, Shibolet O, et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006;101(3):561-8
43. Hyun JG, Barrett TA. Oral tolerance therapy in inflammatory bowel disease. Am J Gastroenterol 2006;101(3):569-71
44. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-9
45. Hafler DA, Kent SC, Pietrusewicz MJ, et al. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann NY Acad Sci 1997;835:120-31
46. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259(5099):1321-4
47. McKown KM, Carbone LD, Bustillo J, et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000;43(5):1054-61
48. Lee S, Scherberg N, DeGroot LJ. Induction of oral tolerance in human autoimmune thyroid disease. Thyroid 1998;8(3):229-34
49. Hauselmann HJ, Caravatti M, Seifert B, et al. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Br J Rheumatol 1998;37(10):1110-7
50. Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann NY Acad Sci 2004;1029:225-38
51. Suzuki A, Van de Water J, Gershwin ME, et al. Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. Dev Immunol 2002;9(2):55-61
52. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000;43(8):1000-4
53. Wildner G, Thurau SR. Oral tolerance in autoimmune uveitis. Dev Ophthalmol 1999;31:67-76
54. Sai P, Rivereau AS, Granier C, et al. Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide-accelerated diabetes. Clin Exp Immunol 1996;105(2):330-7
55. Ramiya VK, Shang XZ, Pharis PG, et al. Antigen based therapies to prevent diabetes in NOD mice. J Autoimmun 1996;9(3):349-56
56. Sakurai Y, Brand DD, Tang B, et al. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther 2006;8(5):R150
57. Dai YD, Carayanniotis G, Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2005;2(3):169-75
58. Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG. Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci 2006;43(3):203-48
59. Pal R, Deshmukh US, Ohyama Y, et al. Evidence for multiple shared antigenic determinants within Ro60 and other lupus-related ribonucleoprotein autoantigens in human autoimmune responses. J Immunol 2005;175(11):7669-77
60. Warren KG, Catz I, Fetenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13(8):887-95
61. Darlington CL. NBI-5788 neurocrine. Curr Opin Investig Drugs 2005;6(7):747-51
62. Spack EG. Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update. Expert Opin Investig Drugs 1997;6(11):1715-27
63. Myers LK, Stuart JM, Seyer JM, et al. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989;170(6):1999-2010
64. Prakken BJ, Roord S, Ronaghy A, et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. Springer Semin Immunopathol 2003;25(1):47-63
65. Puga Yung GL, Le TD, Roord S, et al. Heat shock proteins (HSP) for immunotherapy of rheumatoid arthritis (RA). Inflamm Res 2003;52(11):443-51
66. Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005;366(9479):50-6
67. Sloan-Lancaster J, Shaw AS, Rothbard JB, et al. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994;79(5):913-22
68. Verhoef A, Lamb JR. Threshold signaling of human Th0 cells in activation and anergy: modulation of effector function by altered TCR ligand. J Immunol 2000;164(11):6034-40
69. + dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum 2006;54(3):887-98
70. Mowat AM. Basic mechanisms and clinical implications of oral tolerance. Curr Opin Gastroenterol 1999;15(6):546-56
71. Zhang Y, Chung Y, Bishop C, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci USA 2006;103(31):11695-700
72. Fleeton M, Contractor N, Leon F, et al. Involvement of dendritic cell subsets in the induction of oral tolerance and immunity. Ann NY Acad Sci 2004;1029:60-5
73. Drexler HG, Quentmeier H. FLT3: receptor and ligand. Growth Factors 2004;22(2):71-3
74. Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol 1999;163(7):3668-75
75. Onai N, Obata-Onai A, Schmid MA, et al. Flt3 in regulation of type I interferon-producing cell and dendritic cell development. Ann NY Acad Sci 2007;1106:253-61
76. Inaba K, Metlay JP, Crowley MT, et al. Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 1990;6(2-3):197-206
77. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther 2007;7(8):1275-80
78. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003;170(3):1304-12
79. Enk AH. DCs and cytokines cooperate for the induction of tregs. Ernst Schering Res Found Workshop 2006;6:97-106
80. Corinti S, Albanesi C, La Sala A, et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166(7):4312-8
81. Selenko-Gebauer N, Majdic O, Szekeres A, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003;170(7):3637-44
82. Ureta G, Osorio F, Morales J, et al. Generation of dendritic cells with regulatory properties. Transplant Proc 2007;39(3):633-7
83. Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000;30(7):1813-22
84. Yang J, Bernier SM, Ichim TE, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leuk Biol 2003;74(3):438-47
85. + T cells. J Immunother 2005;28(6):560-3
86. Hill JA, Ichim TE, Kusznieruk KP, et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003;171(2):691-6
87. Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007;178(9):5480-7
88. Popov I, Li M, Zheng X, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther 2006;8(5):R141
89. Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science 2007;317(5838):580
90. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200(3):277-85
91. +CD25hi T-regulatory cells. Blood 2006;108(1):253-61
92. + T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann NY Acad Sci 2005; 1051:506-14
93. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp 2003;252:279-86; discussion 286-90